These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 28693985)

  • 1. Cardiovascular risk markers among obese women using the levonorgestrel-releasing intrauterine system: A randomised controlled trial.
    Zueff LFN; Melo AS; Vieira CS; Martins WP; Ferriani RA
    Obes Res Clin Pract; 2017; 11(6):687-693. PubMed ID: 28693985
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of the levonorgestrel-releasing intrauterine system on cardiovascular risk markers among women with thrombophilia or previous venous thromboembolism.
    Braga GC; Brito MB; Ferriani RA; Oliveira LC; Garcia AA; Pintão MC; Vieira CS
    Int J Gynaecol Obstet; 2020 Mar; 148(3):381-385. PubMed ID: 31778208
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Levonorgestrel-releasing intrauterine system effects on metabolic variables in PCOS.
    Ji L; Jin L; Shao MJ; Hu M; Xu J
    Gynecol Endocrinol; 2023 May; 39(1):2208667. PubMed ID: 37182541
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Levonorgestrel-Releasing Intrauterine System for Women With Polycystic Ovary Syndrome: Metabolic and Clinical Effects.
    da Silva AV; de Melo AS; Barboza RP; de Paula Martins W; Ferriani RA; Vieira CS
    Reprod Sci; 2016 Jul; 23(7):877-84. PubMed ID: 26733500
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Endothelial function in women using levonorgestrel-releasing intrauterine system (LNG-IUS).
    Selim MF; Hussein AF
    Contraception; 2013 Apr; 87(4):396-403. PubMed ID: 23332246
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of progestin-only long-acting contraception on metabolic markers in obese women.
    Bender NM; Segall-Gutierrez P; Najera SO; Stanczyk FZ; Montoro M; Mishell DR
    Contraception; 2013 Sep; 88(3):418-25. PubMed ID: 23410714
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Body weight and composition in users of levonorgestrel-releasing intrauterine system.
    Dal'Ava N; Bahamondes L; Bahamondes MV; de Oliveira Santos A; Monteiro I
    Contraception; 2012 Oct; 86(4):350-3. PubMed ID: 22445431
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Effect of Age, Parity and Body Mass Index on the Efficacy, Safety, Placement and User Satisfaction Associated With Two Low-Dose Levonorgestrel Intrauterine Contraceptive Systems: Subgroup Analyses of Data From a Phase III Trial.
    Gemzell-Danielsson K; Apter D; Hauck B; Schmelter T; Rybowski S; Rosen K; Nelson A
    PLoS One; 2015; 10(9):e0135309. PubMed ID: 26378938
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomised clinical trial to assess satisfaction with the levonorgestrel- releasing intrauterine system inserted at caesarean section compared to postpartum placement.
    Braniff K; Gomez E; Muller R
    Aust N Z J Obstet Gynaecol; 2015 Jun; 55(3):279-83. PubMed ID: 26053465
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quantitative levonorgestrel plasma level measurements in patients with regular and prolonged use of the levonorgestrel-releasing intrauterine system.
    Seeber B; Ziehr SC; Gschlieβer A; Moser C; Mattle V; Seger C; Griesmacher A; Concin N; Concin H; Wildt L
    Contraception; 2012 Oct; 86(4):345-9. PubMed ID: 22402256
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Weight variation in users of depot-medroxyprogesterone acetate, the levonorgestrel-releasing intrauterine system and a copper intrauterine device for up to ten years of use.
    Modesto W; de Nazaré Silva dos Santos P; Correia VM; Borges L; Bahamondes L
    Eur J Contracept Reprod Health Care; 2015 Feb; 20(1):57-63. PubMed ID: 25160484
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A multicentre, open-label, randomised phase III study comparing a new levonorgestrel intrauterine contraceptive system (LNG-IUS 8) with combined oral contraception in young women of reproductive age.
    Borgatta L; Buhling KJ; Rybowski S; Roth K; Rosen K
    Eur J Contracept Reprod Health Care; 2016 Oct; 21(5):372-9. PubMed ID: 27494570
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of hysterectomy or levonorgestrel-releasing intrauterine system on cardiovascular disease risk factors in menorrhagia patients: a 10-year follow-up of a randomised trial.
    Heliövaara-Peippo S; Oksjoki R; Halmesmäki K; Kaaja R; Teperi J; Grenman S; Kivelä A; Surcel HM; Tomas E; Tuppurainen M; Hurskainen R; Paavonen J
    Maturitas; 2011 Aug; 69(4):354-8. PubMed ID: 21684096
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The benefits and risks of using a levonorgestrel-releasing intrauterine system for contraception.
    Mansour D
    Contraception; 2012 Mar; 85(3):224-34. PubMed ID: 22067761
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of intrauterine and oral levonorgestrel administration on serum concentrations of sex hormone-binding globulin, insulin and insulin-like growth factor binding protein-1.
    Pakarinen P; Lähteenmäki P; Rutanen EM
    Acta Obstet Gynecol Scand; 1999 May; 78(5):423-8. PubMed ID: 10326889
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of menorrhagia with a novel 'frameless' intrauterine levonorgestrel-releasing drug delivery system: a pilot study.
    Wildemeersch D; Schacht E
    Eur J Contracept Reprod Health Care; 2001 Jun; 6(2):93-101. PubMed ID: 11518454
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prospective study of the forearm bone mineral density of long-term users of the levonorgestrel-releasing intrauterine system.
    Bahamondes MV; Monteiro I; Castro S; Espejo-Arce X; Bahamondes L
    Hum Reprod; 2010 May; 25(5):1158-64. PubMed ID: 20185512
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mechanism of action of the levonorgestrel-releasing intrauterine system in the treatment of heavy menstrual bleeding.
    Cihangir U; Ebru A; Murat E; Levent Y
    Int J Gynaecol Obstet; 2013 Nov; 123(2):146-9. PubMed ID: 24028852
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomized clinical trial of the effect of intensive versus non-intensive counselling on discontinuation rates due to bleeding disturbances of three long-acting reversible contraceptives.
    Modesto W; Bahamondes MV; Bahamondes L
    Hum Reprod; 2014 Jul; 29(7):1393-9. PubMed ID: 24812309
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of metabolic and inflammatory outcomes in women who used oral contraceptives and the levonorgestrel-releasing intrauterine device in a general population.
    Morin-Papunen L; Martikainen H; McCarthy MI; Franks S; Sovio U; Hartikainen AL; Ruokonen A; Leinonen M; Laitinen J; Järvelin MR; Pouta A
    Am J Obstet Gynecol; 2008 Nov; 199(5):529.e1-529.e10. PubMed ID: 18533124
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.